Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.46 |
| ▸ | RAF1 | P04049 | 5/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20572337 | 1.00 | CTSS (0.46) | CTSSCTSKAAK1RAF1MAPK14 | |
| SCHEMBL28449432 | 0.90 | CTSS (0.47) | CTSSCTSKAAK1CTSBCTSL | |
| SCHEMBL21712650 | 0.83 | CTSS (0.47) | CTSSCTSKAAK1RAF1MAPK14 | |
| SCHEMBL21712651 | 0.83 | CTSS (0.47) | CTSSCTSKAAK1RAF1MAPK14 | |
| SCHEMBL101455 | 0.82 | RAF1 (0.42) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL21712631 | 0.73 | CTSS (0.48) | CTSSCTSKAAK1 | |
| SCHEMBL21712632 | 0.73 | CTSS (0.48) | CTSSCTSKAAK1 | |
| SCHEMBL21712639 | 0.73 | AAK1 (0.42) | AAK1RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL21712638 | 0.73 | AAK1 (0.42) | AAK1RAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL28448428 | 0.72 | CTSS (0.44) | CTSSCTSKAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
| WO-2018217439-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZHANG HAI JUN (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | CDC7, CDK7, CDK17 | CTSS 3106/4885CTSK 1816/4885AAK1 910/4885 |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | CDC7, CDK7, CDK17 | CTSS 3106/4885CTSK 1816/4885AAK1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.